Introduction
Granulocytic sarcoma (chloroma) is a rare extramedullary tumour composed of primitive cells of the granulocytic series. It was first described by Burns in 1811 and the name chloroma was used by King in 18532 to emphasize the greenish colour often found in the tumour which fades on exposure to air.
The tumour occurs in a variety of clinical settings and is often difficult to diagnose. It Table I . Cases 3, 6 and 7 presented with syndromes clinically indistinguishable from non-Hodgkin lymphoma. Only one of the patients (case no. 7) had had a bone marrow examination done before attending the Royal Marsden Hospital and all of them had symptoms relating to their mass for between 2-7 months before the aspiration. In 3 cases (nos. 3, 4, 5) the finding of acute myeloid leukaemia prompted re-examination of the biopsy material with the use of the definitive CAE stain ( Figure 1) .
Although all the patients eventually died of their disease, patients who were treated with the regimens used for acute myeloid leukaemia had complete remissions lasting from 2-16 months (Table II) regimens if survival is to be increased.6'7'9"0 The clinical and pathological diagnosis of granulocytic sarcoma continues to be a problem. It is essential to bear this condition in mind when confronted by problematic 'undifferentiated tumours' existing in soft tissues, bone or parenchymal organs. Bone marrow examination must be made and biopsy material stained with CAE. In addition, when doubt exists about the diagnosis of non-Hodgkin lymphoma -particularly in cases which behave atypically, such as failure to remit on conventional chemotherapy -then the biopsy material should be re-examined for CAE positivity.
If a granulocytic sarcoma is diagnosed in the absence of leukaemia we suggest that treatment with an acute myeloid leukaemia regimen should be used and consideration be given to bone marrow transplantation in remission.
